Sirolimus for Kaposiform Hemangioendothelioma and Kasabach-Merritt Phenomenon in a Neonate
The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ )..
We present a case of a neonate born with kaposiform hemangioendothelioma (KHE), complicated by Kasabach-Merritt phenomenon (KMP) and other serious conditions, who was successfully treated with sirolimus. In addition to complications from thrombocytopenia and fluid overload, during the course of therapy, our patient experienced supratherapeutic drug levels at the commonly accepted starting dose of sirolimus. Patients with KHE and KMP should be closely monitored for potential complications of both the initial disease and unexpected side effects of treatments.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
AJP reports - 10(2020), 4 vom: 12. Okt., Seite e390-e394 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cabrera, Trevor B [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Case Reports |
|---|
| Anmerkungen: |
Date Revised 21.11.2020 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1055/s-0040-1718901 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM317820176 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM317820176 | ||
| 003 | DE-627 | ||
| 005 | 20231225164050.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1055/s-0040-1718901 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1059.xml |
| 035 | |a (DE-627)NLM317820176 | ||
| 035 | |a (NLM)33214934 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cabrera, Trevor B |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Sirolimus for Kaposiform Hemangioendothelioma and Kasabach-Merritt Phenomenon in a Neonate |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 21.11.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ). | ||
| 520 | |a We present a case of a neonate born with kaposiform hemangioendothelioma (KHE), complicated by Kasabach-Merritt phenomenon (KMP) and other serious conditions, who was successfully treated with sirolimus. In addition to complications from thrombocytopenia and fluid overload, during the course of therapy, our patient experienced supratherapeutic drug levels at the commonly accepted starting dose of sirolimus. Patients with KHE and KMP should be closely monitored for potential complications of both the initial disease and unexpected side effects of treatments | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Kasabach-Merritt phenomenon | |
| 650 | 4 | |a kaposiform hemangioendothelioma | |
| 650 | 4 | |a sirolimus | |
| 700 | 1 | |a Speer, Allison L |e verfasserin |4 aut | |
| 700 | 1 | |a Greives, Matthew R |e verfasserin |4 aut | |
| 700 | 1 | |a Goff, Donna A |e verfasserin |4 aut | |
| 700 | 1 | |a Menon, Neethu M |e verfasserin |4 aut | |
| 700 | 1 | |a Reynolds, Eric W |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t AJP reports |d 2011 |g 10(2020), 4 vom: 12. Okt., Seite e390-e394 |w (DE-627)NLM227766237 |x 2157-6998 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2020 |g number:4 |g day:12 |g month:10 |g pages:e390-e394 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1055/s-0040-1718901 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2020 |e 4 |b 12 |c 10 |h e390-e394 | ||